Strategic merger Prioritize partnerships and sales conversations that leverage Orbit’s integrated clinical-stage retinal gene therapy platform resulting from the Gyroscope Therapeutics merger, highlighting seamless delivery, manufacturing quality, and potential to scale surgical delivery solutions.

Retinal gene therapy focus Target ophthalmology and biotech channels with offerings around precise sub-retinal delivery systems, surgical training, and curative therapeutics, aligning value with customers pursuing blinding condition treatments.

Early-stage monetization Explore pilot collaborations, research licenses, or shared-risk agreements given the revenue range and clinical-stage status, emphasizing joint development opportunities and access to cutting-edge delivery platforms.

Global footprint Leverage presence in both the US and UK to propose cross-border partnerships, regulatory support, and global manufacturing capabilities that appeal to multinational ophthalmology developers and contract manufacturing opportunities.

Tech-enabled advantage Position the company’s technology stack and telemetry-enabled training assets as differentiators in surgeon education and deployment efficiency, offering scalable training programs and implementation packages to partners.